Claim definition

US FDA Sunscreen Label Claims: Water Resistant (40/80 min), Broad Spectrum, and SPF

Under 21 CFR 201.327 (eff. June 18, 2012), Water Resistant labels only 40 or 80 minutes tested, Broad Spectrum requires critical wavelength >=370nm, SPF is measured at 2 mg/cm2 in lab.

Checked

Issuer

U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research.

Definition

Three US OTC sunscreen Drug Facts claims defined by FDA test under 21 CFR 201.327: (1) Water Resistant 40 or 80 minutes - SPF measured before/after a defined water immersion/activity protocol; labeled duration is immersion time over which tested SPF was maintained. (2) Broad Spectrum - in vitro UV absorbance scan requiring critical wavelength >=370nm. (3) SPF number - in vivo human panel erythema test with product applied at fixed 2.00 +/- 0.05 mg/cm2 lab dose. No brand named; describes claim definitions, not product compliance.

Guarantees
  • Water Resistant 40/80 minutes: tested SPF was maintained after the specified 40- or 80-minute water immersion/activity protocol (20-min water activity cycles separated by 15-min untoweled rest); only '40 minutes' or '80 minutes' may be labeled, per 201.327(a) and (i).
  • Broad Spectrum: absorbance spectrum on PMMA plate substrate yielded a critical wavelength (point where 90% of cumulative UV absorbance from 290-400nm is reached) of at least 370nm, per 201.327(j).
  • SPF number: in vivo test with product applied at a fixed, weighed 2.00 +/- 0.05 mg/cm2 dose delayed onset of UV erythema in human panelists by the stated multiple versus unprotected skin.
Scope level

Validated per formulation/product as tested in a specific lab study, not per company, brand line, batch, or facility. No FDA certification mark or seal is issued; manufacturers self-certify by holding required test data on file and are subject to FDA enforcement (inspection, warning letters, misbranding action) rather than pre-market approval or a public pass/fail certificate per SKU.

Jurisdiction

United States (FDA, FD&C Act OTC drug labeling authority) only. Other jurisdictions differ and are not covered: EU/UK use ISO 24444 SPF plus ISO 24442/UVA-PF ratio logo; Japan/Korea use PA+ system; Australia/NZ use AS/NZS 2604.

Change history
  • May 21, 1999: FDA publishes original sunscreen OTC final monograph (21 CFR Part 352), including SPF and early water-resistance terminology.
  • Effective June 4, 2004: Part 352 stayed indefinitely pending further FDA GRASE action.
  • June 17, 2011: FDA final rule (76 FR 35620) creates 21 CFR 201.327 - current 40/80-minute water-resistance test and label language, broad-spectrum critical-wavelength (>=370nm) test, prohibition of 'waterproof'/'sweatproof'/'sunblock' claims, SPF-based warning labeling. Effective June 18, 2012.
  • May 11, 2012: FDA order delays compliance dates six months to December 17, 2012 (>=$25,000 annual sales) and December 17, 2013 (below that threshold).
  • March 27, 2020: CARES Act deems the stayed Part 352 monograph a 'final administrative order' (M020) for active-ingredient GRASE status; 201.327 labeling/testing requirements remain separately in force, unaltered.
  • September 24/27, 2021: FDA issues proposed order to amend Monograph M020 (e.g., proposed SPF label cap, active-ingredient updates). Not finalized as of this record's date; the 40/80-minute, >=370nm, and 2 mg/cm2 test definitions in 201.327 remain controlling and unchanged.
Effective date

Final rule published June 17, 2011; effective June 18, 2012. Compliance dates delayed six months by FDA order of May 11, 2012 to December 17, 2012 (firms with >=$25,000 annual OTC sunscreen sales) and December 17, 2013 (firms below that threshold). As of this record's date (2026-08-23), 201.327 remains controlling; a 2021 proposed order amending Monograph M020 has not been finalized and does not change these three test definitions.

Registry lookup

Not published in a per-product, per-claim searchable form. FDA maintains no public registry mapping individual sunscreen SKUs to their water-resistance, broad-spectrum, or SPF test data. Products receive National Drug Code (NDC) identifiers searchable in FDA's NDC Directory, and monograph rulemaking dockets exist at accessdata.fda.gov/drugsatfda_docs/omuf/, but neither contains individual product test dossiers. Stated plainly: no public consumer lookup tool exists to verify a specific product's underlying test data - this is not published.

Standard version

21 CFR 201.327, codified from FDA final rule 76 FR 35620 (June 17, 2011). Water resistance procedure at 201.327(i)(7); prohibited terms at 201.327(g); broad spectrum critical wavelength test at 201.327(j) (adapted from ISO 24443, PMMA plate substrate); SPF in vivo method requires 2.00 +/- 0.05 mg/cm2 application, minimum 10 evaluable subjects. Note: 21 CFR Part 352 (1999 monograph) is stayed indefinitely since 2004 and was 'deemed final' under the 2020 CARES Act for active-ingredient GRASE status; 201.327 is a separate, still-active regulation covering the claims in this record.

Identifier format

No dedicated claim-certificate identifier is issued for these three claims. The only applicable FDA identifier is the National Drug Code (NDC), format 4-4-2, 5-3-2, or 5-4-1 digit segments (labeler-product-package, e.g. 12345-6789-01), which identifies the marketed drug product generally, not the water-resistance/broad-spectrum/SPF claim status, and does not appear on-label as a claim ID.

Does not guarantee
  • Water Resistant does NOT mean 'waterproof' or 'sweatproof' - both terms are prohibited under 201.327(g) as misbranding. Does not guarantee protection beyond the tested duration, under toweling (test protocol forbids toweling but real users often towel off), or under activity patterns unlike the tested cycle.
  • Broad Spectrum passing does NOT quantify the amount of UVA protection and gives no graded UVA number (unlike Japan's PA+ system or the EU UVA-PF:SPF logo) - it only confirms the 370nm critical-wavelength threshold was met, and says nothing about visible-light or IR protection.
  • SPF number does NOT reflect real-world protection for most users because it is measured at a fixed 2 mg/cm2 film applied by trained technicians. Published studies found consumer application commonly below that: roughly 0.39-1.5 mg/cm2 in various designs, and a large US online-survey estimate of median ~1.78 mg/cm2 (face) and ~1.35 mg/cm2 (body) - both under 2 mg/cm2. Because protection scales non-linearly with thickness, under-application meaningfully cuts effective protection; a King's College London study (Acta Dermato-Venereologica, 2018) found thinner real-world application of SPF 50 sunscreen gave roughly 40% of labeled protection. SPF also does not measure UVA protection and does not guarantee any specific wear duration.

Sources

  1. primary-regulatory eCFR - 21 CFR 201.327
  2. primary-regulatory Cornell LII - 21 CFR 201.327 full text
  3. primary-regulatory FDA - Labeling and Effectiveness Testing Small Entity Compliance Guide
  4. primary-regulatory Federal Register - 76 FR 35620, June 17, 2011 final rule
  5. primary-regulatory Federal Register - Delay of Compliance Dates, May 11, 2012
  6. primary-regulatory eCFR - 21 CFR Part 352 [Stayed Indefinitely]
  7. primary-regulatory Federal Register - Proposed Order amending OTC Monograph M020, 2021
  8. primary-regulatory FDA - OTC Monograph M020 Sunscreen Drug Products (Sept 24, 2021)
  9. primary-regulatory FDA - Study Protocol, In vivo Determination of SPF (Static)
  10. secondary-media ScienceDaily - Sunscreen users receive less than half the protection they think (2018)
  11. primary-academic Petersen & Wulf - Application of sunscreen: theory and reality, Photodermatol Photoimmunol Photomed (2014)
  12. primary-academic PMC - Online survey of consumer sunscreen application thickness
  13. secondary-media Eurofins - FDA Broad Spectrum Testing overview

All research records · Corrections: see our corrections policy.